Drugmakers cut prices on average by more than 60% to get on China's 2022 NDRL list —...

[cafead]

via China’s National Reimbursement Drug List (NRDL) is a crystal clear example of the country’s bargaining power in the biotech and pharma market, as more firms have reportedly agreed to cut their prices for 67 new medicines to be included in its national medical insurance coverage starting in January.

article source